The hospital acquired infection control market reached $16 billion in 2016 and will continue to grow thanks to several factors.
Here are five things to know:
1. The market focuses on nosocomial infections and infections developed during hospitalization or stays at health facilities. Testing products, device sterilization, specific cleaning products and HAI treatments are included in the market figure.
2. Controlling these infections, as many of the bacteria that cause infection evolve and develop resistance to antimicrobials. New approaches to preventing, diagnosing, and treating such infections will be required for the long-term.
4. HHS strives to combat HAIs by reducing Catheter-Associated Urinary Tract Infection, Central Line-associated Bloodstream Infections, Clostridium difficile, methicillin-resistant Staphylococcus aureus and surgical site infections.
5. Testing for nosocomial infections is a fast-growing market segment thanks to increased awareness of infections. The treatment segment is the HAI market's weakest element due to a poor development pipeline. Advanced products capable of treating serious infections offset the challenges, however and may help make it profitable down the road.
More articles on quality & infection control:
OSS Health installs 2 Xenex disinfectant robots — 4 notes